Functional Constipation Clinical Trial
Official title:
A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants With Functional Constipation (FC) or Irritable Bowel Syndrome With Constipation (IBS-C)
Verified date | June 2024 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants (6-17 years of age) with FC or IBS-C who completed study intervention in studies LIN-MD-62, LIN-MD-63, orLIN-MD-64 based on the individual study criteria.
Status | Active, not recruiting |
Enrollment | 389 |
Est. completion date | June 5, 2025 |
Est. primary completion date | June 5, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 18 Years |
Eligibility | Inclusion Criteria: - Participant weighs = 18 kg at the time the parent/guardian/LAR and/or caregiver has provided signed consent. - Female participants who have had their first menstrual period and are sexually active must agree to use a reliable form of contraception. - Participants must have completed study intervention in their lead-in study. Inclusion Criteria for Phase 2 LIN-MD-62 or Phase 2 LIN-MD-63 and Phase 3 LIN-MD-64 completers who enroll in LIN-MD-66 after >28 days from last study intervention: - Female participants of childbearing potential must have a negative serum pregnancy test at the Screening Visit (Visit 1) and negative urine pregnancy test prior to the first dose on the Day 1 Visit (Visit 2). - LIN-MD-63 completers only: Participants meet Rome III criteria for child/adolescent IBS: At least once per week for at least 2 months before the LIN-MD-66 Screening Visit (Visit 1), the participant has experienced abdominal discomfort (an uncomfortable sensation not described as pain) or pain associated with 2 or more of the following at least 25% of the time: - a) Improvement with defecation - b) Onset associated with a change in frequency of stool - c) Onset associated with a change in form (appearance) of stool - Participants meet modified Rome III criteria for child/adolescent FC: For at least 2 months before the LIN-MD-66 Screening Visit (Visit 1), the participant has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) in the toilet per week. In addition, at least once per week, participant meets 1 or more of the following: - a) History of retentive posturing or excessive volitional stool retention - b) History of painful or hard BMs - c) Presence of a large fecal mass in the rectum - d) History of large diameter stools that may obstruct the toilet - e) At least 1 episode of fecal incontinence per week Exclusion Criteria: - Participant has a known allergy or sensitivity to the study intervention or its components or other medications in the same drug class. - Participant received an investigational drug, other than linaclotide, during the 30 days before the Screening Visit (Visit 1) or is planning to receive an investigational drug (other than that administered during this study) or use an investigational device at any time during the study. - Female participants who are currently pregnant or nursing, or plan to become pregnant or nurse during the clinical study. - Participant has required manual disimpaction any time prior to study intervention or disimpaction during in-patient hospitalization within 1 year prior to study intervention. - Participant has any of the following conditions: - a) Down's syndrome or any other chromosomal disorder - b) Anatomic malformations (eg, imperforate anus, anal stenosis, anterior displaced anus) - c) Intestinal nerve or muscle disorders (eg, Hirschprung disease, visceral myopathies, visceral neuropathies) - d) Neuropathic conditions (eg, spinal cord abnormalities, neurofibromatosis, tethered cord, spinal cord trauma) - e) Neurodevelopmental disabilities (early-onset, chronic disorders that share the essential feature of a predominant disturbance in the acquisition of cognitive, motor, language, or social skills, which has a significant and continuing impact on the developmental progress of an individual) producing a cognitive delay that precludes comprehension by the participant. - Participant has a mechanical bowel obstruction or pseudo-obstruction. - Participant currently has both unexplained and clinically significant alarm symptoms (lower GI bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process. - Participant has an active anal fissure (Note: history of anal fissure is not an exclusion). - Participant has had surgery that meets any of the following criteria: - a) Bariatric surgery for treatment of obesity, or surgery to remove a segment of the GI tract at any time before the Screening Visit (Visit 1). - b) Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit (Visit 1) - c) An appendectomy or cholecystectomy during the 60 days before the Screening Visit - d) Other major surgery during the 30 days before the Screening Visit (Visit 1) - Participant is receiving enteral tube feeding - Participants who have positive urine drug screen results for cocaine, barbiturates, opiates, or cannabinoids will be excluded from study participation. Exclusion Criteria for LIN-MD-62, LIN-MD-63 and LIN-MD-64 Completers Who Enroll in LIN-MD-66 > 28 Days From Last Study Intervention: - Participant has a history of nonretentive fecal incontinence - For LIN-MD-62 and LIN-MD-64 completers only: Participant meets Rome III criteria for child/adolescent IBS: at least once per week for at least 2 months before Screening (Visit 1), the participant has experienced abdominal discomfort (an uncomfortable sensation not described as pain) or pain associated with 2 or more of the following at least 25% of the time: - a) Improvement with defecation - b) Onset associated with a change in the frequency of stool - c) Onset associated with a change in form (appearance) of stool - Participant has a history of drug or alcohol abuse - Participant has any of the following conditions: - a) Celiac disease, or positive serological test for celiac disease and the condition has not been ruled out by endoscopic biopsy - b) Cystic fibrosis - c) Hypothyroidism that is untreated or treated with thyroid hormone at a dose that has not been stable for at least 3 months prior to the Screening (Visit 1) - d) Lead toxicity, hypercalcemia - e) Inflammatory bowel disease - f) Childhood functional abdominal pain syndrome - g) Childhood functional abdominal pain - h) Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study - i) Lactose intolerance that is associated with abdominal pain or discomfort and could confound the assessments in this study - j) History of cancer other than treated basal cell carcinoma of the skin. (Note: Participants with a history of cancer are allowed provided that the malignancy has been in a complete remission for at least 5 years before the Randomization Visit. A complete remission is defined as the disappearance of all signs of cancer in response to treatment.) - k) History of diabetic neuropathy - Participants who have positive urine drug screen results for cocaine, barbiturates, opiates, or cannabinoids. |
Country | Name | City | State |
---|---|---|---|
Canada | London Health Sciences Center- University Hospital /ID# 234309 | London | Ontario |
Canada | Bluewater Clinical Research Group Inc /ID# 234618 | Sarnia | Ontario |
Canada | Stouffville Medical Centre /ID# 234619 | Stouffville | Ontario |
Israel | Hadassah Hebrew University Hospital - Ein Kerem /ID# 234735 | Jerusalem | Yerushalayim |
Israel | The Chaim Sheba Medical Center /ID# 236760 | Ramat Gan | Tel-Aviv |
Israel | The Baruch Padeh Medical Center Poriya /ID# 234768 | Tiberias | HaTsafon |
Netherlands | Duplicate_Academisch Medisch Centrum /ID# 237116 | Amsterdam | Noord-Holland |
United States | University of New Mexico /ID# 236983 | Albuquerque | New Mexico |
United States | Advanced Research Center /ID# 237960 | Anaheim | California |
United States | Children's Ctr Digestive, US /ID# 237574 | Atlanta | Georgia |
United States | Children's Healthcare of Atlanta - Ferry Rd /ID# 237005 | Atlanta | Georgia |
United States | Treken Primary Care /ID# 234645 | Atlanta | Georgia |
United States | Lynn Institute of Denver /ID# 238086 | Aurora | Colorado |
United States | Central Research Associates /ID# 237953 | Birmingham | Alabama |
United States | River Birch Research Alliance /ID# 237963 | Blue Ridge | Georgia |
United States | Private Practice - Dr. Craig Spiegel /ID# 234545 | Bridgeton | Missouri |
United States | Advantage Clinical Trials /ID# 237932 | Bronx | New York |
United States | Coastal Pediatric Research - West Ashley B /ID# 234678 | Charleston | South Carolina |
United States | Kindred Medical Institute, LLC /ID# 237367 | Corona | California |
United States | Dolphin Medical Research /ID# 234676 | Doral | Florida |
United States | Prohealth Research Center /ID# 234659 | Doral | Florida |
United States | Medclinical Research Partners LLC/ Foundation Pediatrics /ID# 234566 | East Orange | New Jersey |
United States | GI associates and Endoscopy Ce /ID# 237969 | Flowood | Mississippi |
United States | G & L Research, LLC /ID# 238093 | Foley | Alabama |
United States | Cook Children's Med. Center /ID# 237536 | Fort Worth | Texas |
United States | Office of Maria Ona /ID# 234539 | Franklin | Virginia |
United States | East Carolina University - Brody School of Medicine /ID# 237509 | Greenville | North Carolina |
United States | Valley Institute of Research /ID# 234475 | Harlingen | Texas |
United States | Amedica Research Institute Inc /ID# 234666 | Hialeah | Florida |
United States | HealthStar Research of Hot Springs PLLC /ID# 234608 | Hot Springs | Arkansas |
United States | Cullen Research /ID# 234482 | Houston | Texas |
United States | Pioneer Research Solutions - Houston /ID# 236935 | Houston | Texas |
United States | Vilo Research Group Inc /ID# 238228 | Houston | Texas |
United States | The Jackson Clinic, PA /ID# 236772 | Jackson | Tennessee |
United States | Nemours Childrens Specialty Care /ID# 237991 | Jacksonville | Florida |
United States | Accellacare of Knoxville /ID# 234462 | Jefferson City | Tennessee |
United States | Michael W. Simon, MD, PSC /ID# 236516 | Lexington | Kentucky |
United States | Applied Research Center of Arkansas /ID# 238069 | Little Rock | Arkansas |
United States | Preferred Research Partners /ID# 237109 | Little Rock | Arkansas |
United States | Elite Clinical Research /ID# 234651 | Miami | Florida |
United States | My Preferred Research LLC /ID# 237943 | Miami | Florida |
United States | South Miami Medical & Research Group Inc. /ID# 234654 | Miami | Florida |
United States | Valencia Medical & Research Center /ID# 234671 | Miami | Florida |
United States | MNGI Digestive Health, P. A. /ID# 234437 | Minneapolis | Minnesota |
United States | Advanced Research for Health Improvement /ID# 238253 | Naples | Florida |
United States | Columbia University Irving Medical Center /ID# 235686 | New York | New York |
United States | Health Research of Hampton Roads, Inc. (HRHR) /ID# 237252 | Newport News | Virginia |
United States | IPS Research Company /ID# 237669 | Oklahoma City | Oklahoma |
United States | Univ Oklahoma HSC /ID# 237546 | Oklahoma City | Oklahoma |
United States | Nemours Children's Hospital /ID# 234429 | Orlando | Florida |
United States | Pediatric & Adult Research Center /ID# 234681 | Orlando | Florida |
United States | Oviedo Medical Research /ID# 234692 | Oviedo | Florida |
United States | Center for Clinical Trials LLC /ID# 234629 | Paramount | California |
United States | AIM Trials /ID# 236364 | Plano | Texas |
United States | David M. Headley, MD, P.A. /ID# 238216 | Port Gibson | Mississippi |
United States | Rhode Island Hospital /ID# 237861 | Providence | Rhode Island |
United States | Clinical Research Partners, LLC /ID# 237158 | Richmond | Virginia |
United States | Chrysalis Clinical Research /ID# 234515 | Saint George | Utah |
United States | Sun Research Institute /ID# 236932 | San Antonio | Texas |
United States | Medical Ctr for Clin Research /ID# 236911 | San Diego | California |
United States | The Center for Clinical Trials Inc. /ID# 234605 | Saraland | Alabama |
United States | Frontier Clinical Research, LLC - Scottdale /ID# 238022 | Scottdale | Pennsylvania |
United States | Virgo Carter Pediatrics /ID# 234518 | Silver Spring | Maryland |
United States | Frontier Clinical Research /ID# 237923 | Smithfield | Pennsylvania |
United States | PMG Research of Piedmont Healthcare-Statesville /ID# 238257 | Statesville | North Carolina |
United States | Clinical Research Institute /ID# 234702 | Stockbridge | Georgia |
United States | Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 236342 | Stockbridge | Georgia |
United States | Coastal Pediatric Research - Summerville /ID# 234674 | Summerville | South Carolina |
United States | Duplicate_Multicare Institute for Research and Innovation /ID# 236979 | Tacoma | Washington |
United States | Children's National Medical Center /ID# 234417 | Washington | District of Columbia |
United States | ClinPoint Trials /ID# 236615 | Waxahachie | Texas |
United States | KU Wichita Center for Clinical Research /ID# 234500 | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
AbbVie | Ironwood Pharmaceuticals, Inc. |
United States, Canada, Israel, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Treatment Emergent Adverse Events | Number of Participants With Treatment-Emergent Adverse Events (TEAEs). | 24 to 52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04506801 -
The Effect of Probiotics on Functional Constipation in the Elderly
|
N/A | |
Completed |
NCT04620161 -
A Proof of Concept Study of Pradigastat in Patients With Functional Constipation
|
Phase 2 | |
Active, not recruiting |
NCT02361749 -
Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation
|
Phase 4 | |
Completed |
NCT03054805 -
The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation
|
Phase 4 | |
Not yet recruiting |
NCT01913665 -
The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation
|
N/A | |
Completed |
NCT01348152 -
Effect of TU-100 in Patients With Functional Constipation
|
Phase 2 | |
Completed |
NCT01622972 -
Mode of Action of Moviprep
|
Phase 4 | |
Completed |
NCT01212146 -
Probiotic-enriched Artichoke in Functional Constipation
|
N/A | |
Completed |
NCT04231162 -
Effect of an 8-week Bifidobacterium Lactis HN019 Supplementation on Functional Constipation
|
N/A | |
Not yet recruiting |
NCT03639142 -
Dried Plums (Prunes) vs. Polyethylene Glycol 4000 for Treatment of Functional Constipation in Children
|
Phase 3 | |
Recruiting |
NCT04918329 -
Functional Digestive Disorders Observatory
|
||
Completed |
NCT02592200 -
Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women
|
N/A | |
Completed |
NCT03707002 -
Effect of scFOS on Increase in Stool Frequency in Constipated People
|
N/A | |
Recruiting |
NCT06083311 -
The Efficacy of a Probiotic for Functional Constipation (FC)
|
N/A | |
Completed |
NCT04110145 -
Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
|
Phase 2 | |
Recruiting |
NCT06196073 -
Visceral Osteopathy in Functional Constipation
|
N/A | |
Completed |
NCT04026113 -
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
|
Phase 3 | |
Completed |
NCT02359396 -
A Randomized, Open-label, Three-arm Study of MZRW on Tolerability, Exposure and Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01847950 -
Effects of scFOS on Stool Frequency in People With Functionnal Constipation
|
N/A | |
Recruiting |
NCT01274793 -
Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy
|
Phase 1 |